Talazoparib Application Scope

Talazoparib, marketed under the brand name Talzenna, is an orally administered poly ADP ribose polymerase (PARP) inhibitor used in the treatment of certain cancers.

Breast Cancer: Talzenna is indicated for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer.
Prostate Cancer: In combination with enzalutamide, talazoparib is approved for the treatment of homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) in adults.

Talazoparib Characteristics

Ingredients: Each capsule contains talazoparib tosylate as the active ingredient.
Properties: Talzenna inhibits PARP enzymes, leading to DNA damage accumulation and cell death, particularly in cancer cells with BRCA mutations.
Specification: Available in capsule form for oral administration.
Packaging Specification: Supplied in bottles containing 30 capsules.
Storage: Store at room temperature, 20°C to 25°C (68°F to 77°F).
Expiry Date: Refer to the packaging for the expiration date.
Executive Standard: Approved by regulatory authorities such as the U.S. FDA and the European Medicines Agency (EMA).
Approval Number: Varies by country; consult local regulatory information.
Date of Revision: Refer to the latest prescribing information for the most recent revision date.
Manufacturer: Pfizer Inc.

Guidelines for the Use of Talazoparib

Dosage and Administration: The recommended dose is 1 mg taken orally once daily, with or without food. Dose adjustments may be necessary for patients with renal impairment.
Adverse Reactions: Common adverse reactions include fatigue, anemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, alopecia, diarrhea, and decreased appetite.
Contraindications: None specified.
Precautions: Monitor blood counts regularly due to the risk of myelosuppression. Advise patients of the potential risk to a fetus and to use effective contraception during treatment.

Talazoparib Interactions

Drug Interactions: Co-administration with P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) inhibitors may increase Talzenna concentrations.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.